Scientific Advisory Board Chairman named.
"Response Biomedical Appoints Dr. Robert Christenson Chairman Of Scientific Advisory Board
VANCOUVER, BRITISH COLUMBIA--Response Biomedical Corp. (RBM:CDNX) today announced the appointment of Robert Christenson, Ph.D., as Chairman of the Company's Scientific Advisory Board. Dr. Christenson, the Director of both Point-of-Care Testing and Clinical Chemistry Laboratories at the University of Maryland Medical Center, is a leader in the clinical use of biochemical markers and the application of point-of-care technology.
``The upcoming clinical trial marks a significant milestone in the development of an exciting new diagnostic technology'', commented Dr. Christenson. ``As Chairman, I look forward to building a strong Scientific Advisory Board and providing guidance as Response moves through its first FDA submission and expands the range of tests available on the RAMP platform.''
Dr. Christenson has been a member of the Board of Directors for the American Association for Clinical Chemistry since 1996. Among his major research interests are the use of biochemical markers for assessing cell injury and improved strategies for utilization of laboratory tests. A Professor of Pathology at the University of Maryland School of Medicine, he has authored more than 100 articles, letters and reviews, contributed more than 20 book chapters, and has presented at numerous conferences on the subject of biochemical markers of myocardial injury.
``Building an active and reputable Scientific Advisory Board will ensure that our R&D programs support a development strategy that meets the needs the medical community,'' said Bill Radvak, President and CEO of Response Biomedical. ``Dr. Christenson's experience in point-of-care diagnostics, cardiac marker testing and clinical trials will be invaluable as Response commercializes the RAMP cardiac markers and moves into new markets.'' |
